리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 07월
페이지 정보:영문 335 Pages
라이선스 & 가격 (부가세 별도)
한글목차
인간성장호르몬 의약품 세계 시장은 2030년까지 52억 달러에 달할 전망
2024년에 40억 달러로 추정되는 인간성장호르몬 의약품 세계 시장은 2024-2030년 분석 기간 동안 CAGR 4.2%로 성장하여 2030년에는 52억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 피하는 CAGR 4.7%를 기록하며 분석 기간 종료시에는 34억 달러에 달할 것으로 예측됩니다. 근육내 부문의 성장률은 분석 기간 동안 CAGR 3.7%로 추정됩니다.
미국 시장은 15억 달러로 추정, 중국은 CAGR 5.8%로 성장 예측
미국의 인간성장호르몬 의약품 시장은 2024년에는 15억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 3억 5,810만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 5.8%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.8%와 3.7%로 예측됩니다. 유럽에서는 독일이 CAGR 약 3.5%로 성장할 것으로 예측됩니다.
세계의 인간성장호르몬 의약품시장 - 주요 동향과 촉진요인 정리
인간성장호르몬(HGH) 의약품은 내인성 성장호르몬의 분비 부족으로 인한 다양한 병적 상태의 치료에 사용되는 성장호르몬의 합성제제입니다. 이러한 질환에는 저신장증을 유발하는 소아 성장호르몬 결핍증과 근육량, 에너지, 삶의 질 저하 등 다양한 증상을 유발하는 성인 성장호르몬 결핍증이 포함되며, HGH는 터너 증후군, 프라더 윌리 증후군, 만성 신부전증 치료에도 사용됩니다. 이러한 치료 용도 외에도 HGH는 근육량 및 운동 능력 향상에도 적용되고 있으며, 스포츠 및 노화 관련 치료에 대한 논란의 여지가 있는 것으로 알려져 있습니다.
HGH 제제 시장은 생명공학 기술의 발전으로 효능과 안전성이 향상됨에 따라 크게 확대되고 있습니다. 재조합 DNA 기술의 개발은 체내에서 생성되는 천연 성장호르몬을 충실하게 모방한 안전하고 효과적인 HGH의 대량 생산을 가능하게 한 매우 중요한 요소입니다. 이는 또한 합성 제품이 출시되기 전에 사용되었던 인간 뇌하수체 추출물에 비해 부작용 발생을 억제하는 데 도움이 되었습니다. 또한, 사용하기 쉬운 주사 펜과 서방형 제제 개발 등 약물전달 시스템의 개선으로 환자의 순응도와 치료 성적이 향상되고 있습니다. HGH의 새로운 응용 가능성이 조사를 통해 계속 밝혀지고 있기 때문에 HGH의 치료 효과의 범위는 계속 확대되고 있습니다.
인간성장호르몬 의약품 시장의 성장은 HGH 치료가 필요한 질병의 유병률 증가, 진단 기술의 발전, 다양한 신체 기능에서 HGH의 역할에 대한 더 깊은 이해 등 여러 가지 요인에 의해 주도되고 있습니다. 진단 방법의 개선으로 소아 및 성인 모두에서 성장호르몬 결핍이 더 자주 확인되고 있으며, 이는 HGH 치료에 대한 수요를 증가시키고 있습니다. 또한, HGH의 용도를 확장하고 약물전달 방법을 개선하기 위한 연구 개발이 진행되고 있는 것도 시장 확대에 크게 기여하고 있습니다. 또한, 노화와 관련된 증상을 관리하고 전반적인 건강 상태를 개선하는 데 있어 HGH 치료의 이점에 대한 소비자의 인식과 수용이 증가하고 있으며, 이는 시장 확대를 더욱 촉진하고 있습니다. 새로운 지역과 새로운 적응증에 대한 규제 당국의 승인 또한 이 시장의 지속적인 성장에 중요한 역할을 하고 있으며, 전 세계적으로 HGH 치료의 보급과 채택을 촉진하고 있습니다.
부문
투여 경로(피하, 근육내, 정맥내, 경구), 유통 채널(병원 약국, 전문 약국, 소매 약국, 온라인 약국), 용도(성장호르몬결핍증, 터너증후군, 특발성 저신장증(ISS), 프라더 윌리-증후군(PWS), 기타 용도)
조사 대상 기업 사례
Eli Lilly and Company
EMD Serono, Inc.
Ambrx, Inc.
Ferring International Center SA
Hanmi Pharmaceuticals Co., Ltd.
Aileron Therapeutics, Inc.
Alteogen, Inc.
CinnaGen Co.
Genexine, Inc.
IPP Group Ltd.
BIOSIDUS SA
Corlison Pte. Limited
Access Pharmaceuticals
ERBAGIL srl
Kynerion S.r.l.
AI 통합
Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
세계 시장 개요
주요 기업
시장 동향과 촉진요인
파이프라인 분석
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
라틴아메리카
중동
아프리카
제4장 경쟁
ksm
영문 목차
영문목차
Global Human Growth Hormone Drugs Market to Reach US$5.2 Billion by 2030
The global market for Human Growth Hormone Drugs estimated at US$4.0 Billion in the year 2024, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Intramuscular segment is estimated at 3.7% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 5.8% CAGR
The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$358.1 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.
Global Human Growth Hormone Drugs Market - Key Trends and Drivers Summarized
Human Growth Hormone (HGH) drugs consist of synthetic forms of growth hormones used to treat various medical conditions caused by inadequate endogenous growth hormone production. These conditions include growth hormone deficiency in children, which can lead to stunted growth, and adult growth hormone deficiency, which may cause a variety of symptoms such as decreased muscle mass, energy, and quality of life. HGH is also used in treating Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. Beyond these therapeutic uses, HGH has applications in improving muscle mass and performance, which has led to its controversial use in sports and aging-related treatments.
The market for HGH drugs has expanded significantly due to advancements in biotechnology that have improved the efficacy and safety of these drugs. The development of recombinant DNA technology has been a pivotal factor in enabling the mass production of safe and effective HGH, which closely mimics the natural growth hormone produced in the body. This has also helped reduce the occurrence of adverse reactions compared to earlier extracts from human pituitary glands, which were used before synthetic versions became available. Furthermore, enhancements in drug delivery systems, including the development of easier-to-use injectable pens and sustained-release formulations, have improved patient compliance and treatment outcomes. As research continues to unveil new potential applications of HGH, such as in recovery from major surgeries and burns, the scope of its therapeutic benefits continues to broaden.
The growth in the human growth hormone drugs market is driven by several factors, including an increase in the prevalence of conditions requiring HGH therapy, advancements in diagnostic techniques, and a better understanding of the role of HGH in various bodily functions. Improved diagnostic methods have led to more frequent identification of growth hormone deficiencies in both children and adults, which, in turn, boosts the demand for HGH treatments. Additionally, ongoing research and development efforts aimed at expanding the applications of HGH and improving drug delivery methods are significant contributors to market growth. Moreover, there is an increasing consumer awareness and acceptance of the benefits of HGH therapy in managing age-related conditions and improving overall health outcomes, which further stimulates market expansion. Regulatory approvals in new regions and for new indications also play a crucial role in the sustained growth of this market, facilitating the wider availability and adoption of HGH therapies globally.
SCOPE OF STUDY:
The report analyzes the Human Growth Hormone Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Route of Administration (Subcutaneous, Intramuscular, Intravenous, Oral); Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy, Online Pharmacy); Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS), Other Applications)
Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Select Competitors (Total 46 Featured) -
Eli Lilly and Company
EMD Serono, Inc.
Ambrx, Inc.
Ferring International Center SA
Hanmi Pharmaceuticals Co., Ltd.
Aileron Therapeutics, Inc.
Alteogen, Inc.
CinnaGen Co.
Genexine, Inc.
IPP Group Ltd.
BIOSIDUS SA
Corlison Pte. Limited
Access Pharmaceuticals
ERBAGIL srl
Kynerion S.r.l.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Human Growth Hormone Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
A Prelude to Human Growth Hormones
Recombinant Human Growth Hormones
Evolution of Recombinant Human Growth Hormones (hGH)
GLOBAL MARKET OVERVIEW
Global Human Growth Hormone Drugs Market to Witness Steady Growth
List of Select Approved Prescription Daily-dose hGH Products by Indication
List of Select Approved Prescription Weekly-dose hGH Products by Indication
Subcutaneous Route Dominates Human Growth Hormone Drugs Market
Growth Hormone Deficiency Application Leads the Human Growth Hormone Drugs Market
North America and Europe Dominate, Asia-Pacific to Witness Fastest Growth
Market Restraints
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
High Prevalence of Growth Hormone Deficiency Disorders
Pediatric GHD Rules, while Adult GHD Remains Underserved
Worldwide Recombinant Human Growth Hormone Market by Indication (2020): Percentage Breakdown of Value Sales for Pediatric GHD; Adult GHD, Turner Syndrome & Idiopathic Short Stature; and Others
Long-Acting hGH Drugs - A Game Changer for the Human Growth Hormone Drugs Market
Approval of Novo Nordisk's Once-Weekly Sogroya to Transform the Market Landscape
Other Noteworthy Developments in the Long Acting hGH Space
Patent Expiry Paves Way for the Emergence of Biosimilars
Strong Innovation Drive Takes Hold of the hGH Industry
Manufacturers Bet on Novel Drug Delivery Technologies
Growing Non-Prescription/Off-Label Usage - A Potential Health Hazard
Needle-less Drug Delivery Systems to Wipe Out of Syringes
Drug Delivery Device Options for Marketed hGH Products
Major Growth Restraining Factors
Complex Delivery System
High Cost of hGH Treatment
Biosimilars Threaten Revenue Growth Erosion
PIPELINE ANALYSIS
Select Daily and Long-Acting Human Growth Hormone Products List in Phase III Pipeline
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 2: World Historic Review for Human Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 3: World 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 5: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 6: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 8: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 9: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 11: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 12: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 14: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 15: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 17: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 18: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 20: World Historic Review for Specialty Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 21: World 15-Year Perspective for Specialty Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 23: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 24: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 26: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 27: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 29: World Historic Review for Growth Hormone Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 30: World 15-Year Perspective for Growth Hormone Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 32: World Historic Review for Turner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 33: World 15-Year Perspective for Turner Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 35: World Historic Review for Idiopathic Short Stature (ISS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 36: World 15-Year Perspective for Idiopathic Short Stature (ISS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 37: World Recent Past, Current & Future Analysis for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 38: World Historic Review for Prader-Willi Syndrome (PWS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 39: World 15-Year Perspective for Prader-Willi Syndrome (PWS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 40: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 41: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 42: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 43: World Human Growth Hormone Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
III. MARKET ANALYSIS
UNITED STATES
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 44: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: USA 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: USA 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
CANADA
TABLE 53: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Canada 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Canada 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
JAPAN
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 62: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: Japan 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: Japan 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
CHINA
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 71: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: China 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: China Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: China 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: China Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: China 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
EUROPE
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 80: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Human Growth Hormone Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Human Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
FRANCE
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 92: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: France 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 95: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: France Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: France 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: France Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: France 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
GERMANY
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 101: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Germany 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 104: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Germany 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Germany 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
ITALY
TABLE 110: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: Italy 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 113: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: Italy 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: Italy 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
UNITED KINGDOM
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 119: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: UK 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 122: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: UK Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: UK 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: UK Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: UK 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
SPAIN
TABLE 128: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Spain 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 131: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Spain Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Spain 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 134: Spain Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Spain Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Spain 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
RUSSIA
TABLE 137: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Russia 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 140: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Russia Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Russia 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 143: Russia Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Russia Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Russia 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Rest of Europe Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Rest of Europe Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: Rest of Europe 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Asia-Pacific 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
LATIN AMERICA
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 164: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Latin America Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 167: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Latin America Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 170: Latin America Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Latin America Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: Latin America 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
MIDDLE EAST
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 173: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 179: Middle East Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Middle East Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: Middle East 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030
AFRICA
Human Growth Hormone Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 182: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Africa Historic Review for Human Growth Hormone Drugs by Route Of Administration - Subcutaneous, Intramuscular, Intravenous and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: Africa 15-Year Perspective for Human Growth Hormone Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Subcutaneous, Intramuscular, Intravenous and Oral for the Years 2015, 2025 & 2030
TABLE 185: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Africa Historic Review for Human Growth Hormone Drugs by Distribution Channel - Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: Africa 15-Year Perspective for Human Growth Hormone Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Specialty Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2015, 2025 & 2030
TABLE 188: Africa Recent Past, Current & Future Analysis for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Africa Historic Review for Human Growth Hormone Drugs by Application - Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Africa 15-Year Perspective for Human Growth Hormone Drugs by Application - Percentage Breakdown of Value Sales for Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and Other Applications for the Years 2015, 2025 & 2030